Marksans Pharma gets EIR from USFDA for its Goa facility
New Delhi: Drug firm Marksans Pharma Thursday said it has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility.
The company has received EIR from the United States Food and Drug Administration (USFDA) in respect of inspection of its Goa facility carried out from February 25 to March 6, 2019, Marksans Pharma said in a filing to the BSE.
The Mumbai-headquartered firm is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets.
Read Also: Marksans Pharma gets 8 USFDA observations for its Goa facility
Shares of Marksans Pharma Thursday ended at Rs 22.70 per scrip on the BSE, up 3.89 per cent from its previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd